INMD
Get informed when a big investor buys or sells
+ FollowUndervalued by 139.3% based on the discounted cash flow analysis.
| Market cap | $803.89 Million |
|---|---|
| Enterprise Value | $427.62 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $1.45 |
| Beta | 2.03 |
| Outstanding Shares | 58,903,000 |
| P/E Ratio | 11.18 |
|---|---|
| PEG | -30.88 |
| Price to Sales | 2.33 |
| Price to Book Ratio | 1.4 |
| Enterprise Value to Revenue | 1.14 |
| Enterprise Value to EBIT | 5.4 |
| Enterprise Value to Net Income | 5 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 0.03 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 215.73% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Holdings and activity of institutional investors.
| Ownership % | 0.07%▼ 53.43% |
|---|---|
| Total Invested | $554,218▼ 99.88% |
| Investors Holding | 3▼ 201.00% |
No data
InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radiofrequency ('RF') technology. InMode strives to enable new emerging surgical procedures as we...